<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Carfilzomib: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Carfilzomib: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Carfilzomib: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="86238" href="/d/html/86238.html" rel="external">see "Carfilzomib: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F14791719"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Kyprolis</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52871462"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Kyprolis</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F14641045"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antineoplastic Agent, Proteasome Inhibitor</li></ul></div>
<div class="block doa drugH1Div" id="F14729214"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Calculate carfilzomib dose using actual BSA. Patients with a BSA &gt;2.2 m<sup>2</sup> should be dosed using a BSA of 2.2 m<sup>2</sup>. Dose adjustments for weight changes of ≤20% are not necessary, per manufacturer labeling. Control/optimize hypertension prior to initiating carfilzomib.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Hydration:</i> Adequate hydration is necessary prior to cycle 1, particularly in patients at risk for tumor lysis syndrome or renal toxicity. Consider hydration with both oral fluids (30 mL/kg at least 48 hours prior to day 1 of cycle 1) and with IV fluids (250 to 500 mL of appropriate IV fluid before each dose in cycle 1). If needed, administer an additional 250 to 500 mL of appropriate IV fluid after carfilzomib administration. Continue oral and/or IV hydration in subsequent cycles if necessary. Monitor for evidence of volume overload and adjust hydration based on individual needs.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Prophylaxis:</i> Consider antiviral prophylaxis to decrease the risk of herpes zoster reactivation. Provide thromboprophylaxis when administering in combination with other therapies per institutional and clinical practice guidelines.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Premedication:</i> When administering carfilzomib as monotherapy, premedicate with dexamethasone 4 mg orally or IV when infusing carfilzomib over 10 minutes or with dexamethasone 8 mg orally or IV when infusing carfilzomib over 30 minutes. When using combination therapy, administer the recommended dexamethasone dose (refer to protocol). Premedicate 30 minutes to 4 hours prior to all doses in cycle 1, and as needed with future cycles to reduce the incidence and severity of infusion reaction.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="05af1378-022a-4306-af74-d3754fe350c6">Heart transplantation, desensitization</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Heart transplantation, desensitization (adjunctive) (off-label use): Note: </b>Optimal dose, frequency, and duration of therapy have not been established and vary based on institutional protocols. Administer as part of an appropriate combination regimen. An example regimen is provided.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV: </b>20 mg/m<sup>2</sup> for 6 doses administered on days 1, 2, 8, 9, 15, and 16; cycle may be repeated until clinical endpoints achieved (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33785250']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33785250'])">Ref</a></span>). Escalating doses up to 36 mg/m<sup>2</sup>/dose were used in a single case after inadequate response to the initial cycle (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32506824']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32506824'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ae430848-f7fa-4798-9b99-54e58004344f">Kidney transplantation, desensitization</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Kidney transplantation, desensitization (adjunctive) (off-label use): Note: </b>Optimal dose, frequency, and duration of therapy have not been established and vary based on institutional protocols. Administer as part of an appropriate combination regimen. An example regimen is provided.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV: </b>20 mg/m<sup>2</sup>/day on days 1 and 2; then 27 mg/m<sup>2</sup>/day on days 8, 9, 15, and 16; then 36 mg/m<sup>2</sup>/day on days 29, 30, 36, 37, 43, and 44 (total of 12 doses) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31550069']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31550069'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="89e7c76c-01fb-4d8c-ab3d-e8f181ec9c70">Lung transplantation, antibody-mediated rejection, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Lung transplantation, antibody-mediated rejection, treatment (adjunctive) (off-label use): Note: </b>Optimal dose, frequency, and duration of therapy have not been established and vary based on institutional protocols. Administer as part of an appropriate combination regimen. An example regimen is provided.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV: </b>20 mg/m<sup>2</sup> administered over 10 to 30 minutes for 6 doses administered on days 1, 2, 8, 9, 15, and 16 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28173620','lexi-content-ref-33748409']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28173620','lexi-content-ref-33748409'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="803bf39b-990a-4158-995f-5bf6163854af">Multiple myeloma, newly diagnosed</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Multiple myeloma, newly diagnosed (off-label use):</b> Adults ≥65 years or ineligible for autologous transplant:</p>
<p style="text-indent:-2em;margin-left:4em;">Induction:</p>
<p style="text-indent:-2em;margin-left:6em;">Cycle 1: <b>IV:</b> 20 mg/m<sup>2</sup> over 30 minutes on days 1 and 2, and 36 mg/m<sup>2</sup> over 30 minutes on days 8, 9, 15, and 16 of a 28-day treatment cycle (in combination with cyclophosphamide and dexamethasone) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24855212']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24855212'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Cycles 2 to 9: <b>IV: </b>36 mg/m<sup>2</sup> over 30 minutes on days 1, 2, 8, 9, 15, and 16 of a 28-day treatment cycle (in combination with cyclophosphamide and dexamethasone) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24855212']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24855212'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Maintenance: <b>IV: </b>36 mg/m<sup>2</sup> on days 1, 2, 15, and 16 of a 28-day treatment cycle (as a single-agent) until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24855212']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24855212'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f1c12cde-98c7-41e9-80b8-0893e9934cc7">Multiple myeloma, relapsed/refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Multiple myeloma, relapsed/refractory:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Multiple myeloma, relapsed/refractory, single-agent; 20/27 mg/m<sup>2</sup> twice-weekly regimen:</b></p>
<p style="text-indent:-2em;margin-left:6em;">Cycle 1: <b>IV: </b>20 mg/m<sup>2</sup> over 10 minutes on days 1 and 2; if tolerated, increase dose to 27 mg/m<sup>2</sup> over 10 minutes on days 8, 9, 15, and 16 of a 28-day treatment cycle.</p>
<p style="text-indent:-2em;margin-left:6em;">Cycles 2 to 12: <b>IV: </b>27 mg/m<sup>2</sup> over 10 minutes on days 1, 2, 8, 9, 15, and 16 of a 28-day treatment cycle.</p>
<p style="text-indent:-2em;margin-left:6em;">Cycle 13 and beyond: <b>IV: </b>27 mg/m<sup>2</sup> over 10 minutes on days 1, 2, 15, and 16 of a 28-day treatment cycle; continue until disease progression or unacceptable toxicity.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> In a randomized study, 12 cycles of the 20/27 mg/m<sup>2</sup> regimen were compared to the 20/56 mg/m<sup>2</sup> regimen (both administered in combination with dexamethasone); while there was no significant difference in response rates or progression-free survival, the 20/27 mg/m<sup>2</sup> regimen was associated with a statistically significantly lower incidence of peripheral neuropathy, thrombocytopenia, and fatigue (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32299820']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32299820'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Multiple myeloma, relapsed/refractory, single-agent; 20/56 mg/m<sup>2</sup> twice-weekly regimen:</b></p>
<p style="text-indent:-2em;margin-left:6em;">Cycle 1: <b>IV: </b>20 mg/m<sup>2</sup> over 30 minutes on days 1 and 2; if tolerated, increase dose to 56 mg/m<sup>2</sup> over 30 minutes on days 8, 9, 15, and 16 of a 28-day treatment cycle.</p>
<p style="text-indent:-2em;margin-left:6em;">Cycles 2 to 12: <b>IV: </b>56 mg/m<sup>2</sup> over 30 minutes on days 1, 2, 8, 9, 15, and 16 of a 28-day treatment cycle.</p>
<p style="text-indent:-2em;margin-left:6em;">Cycle 13 and beyond: <b>IV: </b>56 mg/m<sup>2</sup> over 30 minutes on days 1, 2, 15, and 16 of a 28-day treatment cycle; continue until disease progression or unacceptable toxicity.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Multiple myeloma, relapsed/refractory, in combination with lenalidomide and dexamethasone; 20/27 mg/m<sup>2</sup> twice-weekly regimen: </b></p>
<p style="text-indent:-2em;margin-left:6em;">Cycle 1: <b>IV: </b>20 mg/m<sup>2</sup> over 10 minutes on days 1 and 2; if tolerated, increase dose to 27 mg/m<sup>2</sup> over 10 minutes on days 8, 9, 15, and 16 of a 28-day treatment cycle (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25482145']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25482145'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Cycles 2 to 12: <b>IV: </b>27 mg/m<sup>2</sup> over 10 minutes on days 1, 2, 8, 9, 15, and 16 of a 28-day treatment cycle (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25482145']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25482145'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Cycles 13 to 18: <b>IV: </b>27 mg/m<sup>2</sup> over 10 minutes on days 1, 2, 15, and 16 of a 28-day treatment cycle; discontinue carfilzomib after cycle 18; beginning with cycle 19, lenalidomide and dexamethasone may be continued until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25482145']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25482145'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Multiple myeloma, relapsed/refractory, in combination with dexamethasone; 20/56 mg/m<sup>2</sup></b>
<b>twice-weekly </b>
<b>regimen: </b></p>
<p style="text-indent:-2em;margin-left:6em;">Cycle 1: <b>IV: </b>20 mg/m<sup>2</sup> over 30 minutes on days 1 and 2; if tolerated, increase dose to 56 mg/m<sup>2</sup> over 30 minutes on days 8, 9, 15, and 16 of a 28-day treatment cycle (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26671818']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26671818'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Cycle 2 and beyond: <b>IV: </b>56 mg/m<sup>2</sup> over 30 minutes on days 1, 2, 8, 9, 15, and 16 of a 28-day treatment cycle; continue until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26671818']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26671818'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Multiple myeloma, relapsed/refractory, in combination with dexamethasone; 20/70 mg/m<sup>2</sup> once-weekly regimen:</b></p>
<p style="text-indent:-2em;margin-left:6em;">Cycle 1: <b>IV: </b>20 mg/m<sup>2</sup> over 30 minutes on day 1; increase dose to 70 mg/m<sup>2</sup> over 30 minutes on days 8 and 15 of a 28-day treatment cycle (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29866475']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29866475'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Cycle 2 and beyond: <b>IV: </b>70 mg/m<sup>2</sup> over 30 minutes on days 1, 8, and 15 of a 28-day treatment cycle; continue until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29866475']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29866475'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Multiple myeloma, relapsed/refractory, in combination with daratumumab and dexamethasone</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32682484']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32682484'])">Ref</a></span>) <b>or daratumumab/hyaluronidase and dexamethasone; 20/56 mg/m<sup>2</sup> twice-weekly regimen:</b></p>
<p style="text-indent:-2em;margin-left:6em;">Cycle 1: <b>IV: </b>20 mg/m<sup>2</sup> over 30 minutes on days 1 and 2; if tolerated, increase dose to 56 mg/m<sup>2</sup> over 30 minutes on days 8, 9, 15, and 16 of a 28-day treatment cycle.</p>
<p style="text-indent:-2em;margin-left:6em;">Cycles 2 and beyond: <b>IV: </b>56 mg/m<sup>2</sup> over 30 minutes on days 1, 2, 8, 9, 15, and 16 of a 28-day treatment cycle; continue until disease progression or unacceptable toxicity.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Multiple myeloma, relapsed/refractory, in combination with daratumumab and dexamethasone or daratumumab/hyaluronidase and dexamethasone; 20/70 mg/m<sup>2</sup> once-weekly regimen: </b></p>
<p style="text-indent:-2em;margin-left:6em;">Cycle 1: <b>IV: </b>20 mg/m<sup>2</sup> over 30 minutes on day 1; if tolerated, increase dose to 70 mg/m<sup>2</sup> over 30 minutes on days 8 and 15 of a 28-day treatment cycle (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31113777','lexi-content-ref-Moreau.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31113777','lexi-content-ref-Moreau.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Cycles 2 and beyond: <b>IV: </b>70 mg/m<sup>2</sup> over 30 minutes on days 1, 8, and 15 of a 28-day treatment cycle; continue until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31113777','lexi-content-ref-Moreau.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31113777','lexi-content-ref-Moreau.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Multiple myeloma, relapsed/refractory, in combination with isatuximab and dexamethasone; 20/56 mg/m<sup>2</sup> twice-weekly regimen</b></p>
<p style="text-indent:-2em;margin-left:6em;">Cycle 1: <b>IV: </b>20 mg/m<sup>2</sup> over 30 minutes on days 1 and 2; if tolerated, increase dose to 56 mg/m<sup>2</sup> over 30 minutes on days 8, 9, 15, and 16 of a 28-day treatment cycle (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34097854']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34097854'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Cycles 2 and beyond: <b>IV: </b>56 mg/m<sup>2</sup> over 30 minutes on days 1, 2, 8, 9, 15, and 16 of a 28-day treatment cycle; continue until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34097854']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34097854'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Multiple myeloma, relapsed/refractory, in combination with pomalidomide and dexamethasone </b>
<b>(off-label combination); 20/27 mg/m<sup>2</sup> once-weekly regimen:</b></p>
<p style="text-indent:-2em;margin-left:6em;">Cycle 1: <b>IV: </b>20 mg/m<sup>2</sup> over 10 minutes on day 1; if tolerated, increase dose to 27 mg/m<sup>2</sup> over 10 minutes on days 8 and 15 of a 28-day treatment cycle (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29479061']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29479061'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Cycles 2 to 8: <b>IV: </b>27 mg/m<sup>2</sup> over 10 minutes on days 1, 8, and 15 of a 28-day treatment cycle (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29479061']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29479061'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Cycles 9 and beyond (maintenance): <b>IV: </b>27 mg/m<sup>2</sup> over 10 minutes on days 1, 8, and 15 of a 28-day treatment cycle; continue until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29479061']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29479061'])">Ref</a></span>). Refer to protocol for further information.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Multiple myeloma, relapsed/refractory, in combination with pomalidomide and dexamethasone </b>
<b>(off-label combination); 20/27 mg/m<sup>2</sup> twice-weekly regimen:</b></p>
<p style="text-indent:-2em;margin-left:6em;">Cycle 1: <b>IV: </b>20 mg/m<sup>2</sup> over 30 minutes on days 1 and 2; if tolerated, increase dose to 27 mg/m<sup>2</sup> over 30 minutes on days 8, 9, 15, and 16 of a 28-day treatment cycle (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26384354']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26384354'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Cycles 2 to 6: <b>IV: </b>27 mg/m<sup>2</sup> over 30 minutes on days 1, 2, 8, 9, 15, and 16 of a 28-day treatment cycle (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26384354']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26384354'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Cycles 7 and beyond (maintenance): <b>IV: </b>27 mg/m<sup>2</sup> over 30 minutes on days 1, 2, 15, and 16 of a 28-day treatment cycle; continue until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26384354']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26384354'])">Ref</a></span>). Refer to protocol for further information.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ebda9a81-6b8d-4064-acf9-5c892f36549f">Waldenström macroglobulinemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Waldenström macroglobulinemia (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">Induction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24859363']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24859363'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">Cycle 1: <b>IV: </b>20 mg/m<sup>2</sup> over 20 minutes on days 1, 2, 8, and 9 of a 21-day treatment cycle (in combination with dexamethasone and rituximab)</p>
<p style="text-indent:-2em;margin-left:6em;">Cycles 2 to 6: <b>IV: </b>36 mg/m<sup>2</sup> over 30 minutes on days 1, 2, 8, and 9 of a 21-day treatment cycle (in combination with dexamethasone and rituximab)</p>
<p style="text-indent:-2em;margin-left:4em;">Maintenance (started 8 weeks after completion of induction therapy in patients with stable disease or better response): <b>IV: </b>36 mg/m<sup>2</sup> on days 1 and 2 every 8 weeks for 8 cycles (in combination with dexamethasone and rituximab) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24859363']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24859363'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50992129"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Kidney impairment <b>prior</b> to treatment initiation:</i></p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> During treatment, monitor serum creatinine and kidney function closely; new-onset acute kidney injury or severe kidney dysfunction may occur in carfilzomib-treated patients. One population-based study observed a rate of new-onset kidney failure as high as 22%. In addition, case reports of thrombotic microangiopathy have been described with use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24518527','lexi-content-ref-24518528','lexi-content-ref-33475778','lexi-content-ref-36506224','lexi-content-ref-33461512','lexi-content-ref-22833546']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24518527','lexi-content-ref-24518528','lexi-content-ref-33475778','lexi-content-ref-36506224','lexi-content-ref-33461512','lexi-content-ref-22833546'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Altered kidney function:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23364621','lexi-content-ref-26976420','lexi-content-ref-28424963']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23364621','lexi-content-ref-26976420','lexi-content-ref-28424963'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Unlikely to be significantly dialyzable (high protein binding): No supplemental dose or dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23364621','lexi-content-ref-28424963','lexi-content-ref-27018162']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23364621','lexi-content-ref-28424963','lexi-content-ref-27018162'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Peritoneal dialysis:</b> Unlikely to be significantly dialyzable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>): No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>CRRT:</b> No dosage adjustment likely to be necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b> No dosage adjustment likely to be necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Kidney toxicity <b>during </b>treatment</i>: Serum creatinine ≥2 times baseline, CrCl &lt;15 mL/minute or CrCl decreases to ≤50% of baseline, or patient requires hemodialysis: Withhold dose and monitor kidney function. If renal toxicity is due to carfilzomib, resume dosing when kidney function has improved to within 25% of baseline; resume with a reduced dose by 1 dose level (see "Dosing: Adjustment for Toxicity" for dose level reductions). If toxicity is not due to carfilzomib, restart at the discretion of the prescriber.</p></div>
<div class="block doha drugH1Div" id="F50989290"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Preexisting hepatic impairment:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Mild (total bilirubin 1 to 1.5 times ULN and any AST <b>or</b> total bilirubin ≤ULN and AST &gt;ULN) or moderate (total bilirubin &gt;1.5 to 3 times ULN and any AST) impairment: Reduce carfilzomib dose by 25%.</p>
<p style="text-indent:-2em;margin-left:4em;">Severe (bilirubin &gt; 3 times ULN) impairment: There are no dosage adjustments provided in the manufacturer's labeling (a recommended dose has not been in established in patients with bilirubin &gt;3 times ULN and any AST).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hepatotoxicity during treatment: </b>Grade 3 or 4 elevation of bilirubin, transaminases, or other liver abnormalities: Withhold dose until resolved or at baseline. After resolution, if appropriate to reinitiate, consider restarting at 1 dose level reduction (see Dosing: Adjustment for Toxicity for dose level reductions) with frequent monitoring of hepatic function.</p></div>
<div class="block doo drugH1Div" id="F20344399"><span class="drugH1">Dosing: Obesity: Adult</span>
<p style="text-indent:0em;display:inline">
<b>ASCO Guidelines for appropriate chemotherapy dosing in adults with a BMI ≥30 kg/m<sup>2 </sup>with cancer:</b> In general, utilize patient's actual body weight (full weight) for calculation of BSA– or weight-based dosing, particularly when the intent of therapy is curative; manage regimen-related toxicities in the same manner as for patients with a BMI &lt;30 kg/m<sup>2</sup>; if a dose reduction is utilized due to toxicity, may consider resumption of full weight-based dosing with subsequent cycles, if cause of toxicity (eg, hepatic or renal impairment) is clearly established and fully resolved (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33939491']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33939491'])">Ref</a></span>). <b>Note:</b> According to the manufacturer, patients with a BSA &gt;2.2 m<sup>2</sup> should be dosed based upon a maximum BSA of 2.2 m<sup>2</sup>; dose adjustments for weight changes of ≤20% are not necessary.</p></div>
<div class="block dot drugH1Div" id="F14729215"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Carfilzomib dose level reductions for toxicity:</b></p>
<table border="1" frame="border" rules="all">
<caption style="text-align:center;">
<b>Carfilzomib Dose Level Reductions<sup>a</sup></b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead valign="middle">
<tr>
<th align="center">
<p style="text-indent:0em;">Regimen</p></th>
<th align="center">
<p style="text-indent:0em;">Usual dose</p></th>
<th align="center">
<p style="text-indent:0em;">First dose reduction</p></th>
<th align="center">
<p style="text-indent:0em;">Second dose reduction</p></th>
<th align="center">
<p style="text-indent:0em;">Third dose reduction</p></th></tr></thead>
<tfoot valign="middle">
<tr>
<td align="center" colspan="5">
<p style="text-indent:0em;text-align:left;">
<sup>a </sup>Infusion times remain unchanged during dose reduction(s). Concomitant combination anticancer therapies may also require dosage modification; refer to those monographs for dosage adjustment recommendations.</p></td></tr>
<tr>
<td align="center" colspan="5">
<p style="text-indent:0em;text-align:left;">
<sup>b </sup>If toxicity persists, discontinue carfilzomib treatment.</p></td></tr></tfoot>
<tbody valign="middle">
<tr>
<td align="center">
<p style="text-indent:0em;">Carfilzomib, lenalidomide, and dexamethasone; or carfilzomib monotherapy (twice weekly)</p></td>
<td align="center">
<p style="text-indent:0em;">27 mg/m<sup>2</sup></p></td>
<td align="center">
<p style="text-indent:0em;">20 mg/m<sup>2</sup></p></td>
<td align="center">
<p style="text-indent:0em;">15 mg/m<sup>2 b</sup></p></td>
<td align="center"></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Carfilzomib and dexamethasone; or carfilzomib, daratumumab or daratumumab/hyaluronidase, and dexamethasone; or carfilzomib, isatuximab, and dexamethasone; or carfilzomib monotherapy (twice weekly)</p></td>
<td align="center">
<p style="text-indent:0em;">56 mg/m<sup>2</sup></p></td>
<td align="center">
<p style="text-indent:0em;">45 mg/m<sup>2</sup></p></td>
<td align="center">
<p style="text-indent:0em;">36 mg/m<sup>2</sup></p></td>
<td align="center">
<p style="text-indent:0em;">27 mg/m<sup>2 b</sup></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Carfilzomib and dexamethasone; or carfilzomib, daratumumab or daratumumab/hyaluronidase, and dexamethasone (once weekly)</p></td>
<td align="center">
<p style="text-indent:0em;">70 mg/m<sup>2</sup></p></td>
<td align="center">
<p style="text-indent:0em;">56 mg/m<sup>2</sup></p></td>
<td align="center">
<p style="text-indent:0em;">45 mg/m<sup>2</sup></p></td>
<td align="center">
<p style="text-indent:0em;">36 mg/m<sup>2 b</sup></p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hematologic toxicity:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>ANC &lt;500/mm<sup>3</sup>:</i> Withhold dose; continue at same dose level if ANC recovers to ≥500/mm<sup>3</sup>. For subsequent ANC levels &lt;500/mm<sup>3</sup>, withhold dose and consider reducing dose by 1 dose level when resuming carfilzomib when ANC ≥500/mm3.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Neutropenic fever (ANC &lt;500/mm<sup>3</sup> with an oral temperature &gt;38.5°C or 2 consecutive readings of &gt;38°C for 2 hours):</i> Withhold dose; if ANC recovers to baseline and fever resolves, resume at the same dose level.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Platelets: &lt;10,000/mm<sup>3</sup> or evidence of bleeding with thrombocytopenia:</i> Withhold dose; continue at same dose level if platelets recover to ≥10,000/mm<sup>3</sup> and/or bleeding is controlled. For subsequent platelet levels &lt;10,000/mm<sup>3</sup>, withhold dose and consider reducing dose by 1 dose level when resuming carfilzomib when platelets ≥10,000/mm<sup>3</sup>.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Nonhematologic toxicity:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Grade 3 or 4 nonhematologic toxicities:</i> Withhold dose until resolved or at baseline. After resolution, consider restarting the next scheduled treatment at 1 dose level reduction.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Cardiac:</i> Grade 3 or 4, new-onset or worsening of heart failure, decreased left ventricular function, or myocardial ischemia: Withhold dose until resolved or at baseline. After resolution, if considered appropriate to reinitiate, consider restarting at 1 dose level reduction.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Hemorrhage or symptoms of blood loss:</i> Reduce dose or withhold treatment as clinically appropriate.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Hypertension, severe or life-threatening:</i> If hypertension cannot be adequately controlled, withhold dose and evaluate. After resolution, consider if appropriate to reinitiate based on risk versus benefit.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Posterior reversible encephalopathy syndrome: </i>Discontinue carfilzomib if posterior reversible encephalopathy syndrome (PRES) diagnosis is suspected; the safety of reinitiating therapy after PRES diagnosis is not known.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Progressive multifocal leukoencephalopathy:</i> Discontinue carfilzomib if progressive multifocal leukoencephalopathy is suspected; refer to a neurologist.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Pulmonary toxicity:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Acute respiratory distress syndrome, acute respiratory failure, and acute diffuse infiltrative pulmonary disease (drug-induced): Discontinue therapy.</p>
<p style="text-indent:-2em;margin-left:6em;">Pulmonary hypertension: Withhold dose until resolved or at baseline. After resolution, consider if appropriate to reinitiate based on risk versus benefit.</p>
<p style="text-indent:-2em;margin-left:6em;">Grade 3 or 4 dyspnea: Withhold dose until resolved or at baseline. After resolution, consider if appropriate to reinitiate based on risk versus benefit.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Thrombotic microangiopathy:</i> Interrupt carfilzomib and manage appropriately if thrombotic microangiopathy, including thrombocytopenic thrombotic purpura/hemolytic uremic syndrome (TTP/HUS) diagnosis is suspected. If TTP/HUS diagnosis is excluded, may consider reinitiating therapy; the safety of restarting carfilzomib after a TTP/HUS diagnosis is not known.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Tumor lysis syndrome:</i> Interrupt treatment until resolved.</p></div>
<div class="block doe drugH1Div" id="F14729217"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F49210440"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported from monotherapy studies in adults.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Cardiac arrhythmia (13%) (Siegel 2013), chest pain (3% to 21%), hypertension (15% to 42%; including hypertensive crisis), peripheral edema (20% to 21%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypokalemia (14%) (Siegel 2013), hypomagnesemia (14%) (Siegel 2013)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Constipation (11%) (Siegel 2013), decreased appetite (15% to 21%), diarrhea (25% to 27%; grades ≥3: 1% to 4%), nausea (35% to 54%; grades ≥3: 1%), vomiting (17% to 33%; grades ≥3: 1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia (42% to 49%; grades ≥3: 24% to 29%), leukopenia (11%; grade 3/4: 5%) (Siegel 2013), lymphocytopenia (14% to 33%; grades ≥3: 12% to 33%), neutropenia (16%; grade 3/4: 18%) (Siegel 2013), thrombocytopenia (37% to 54%; grades ≥3: 25% to 54%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Chills (12% to 38%), dizziness (11% to 29%), fatigue (40% to 58%), headache (24% to 33%), insomnia (13% to 29%), peripheral neuropathy (≤19%; including dysesthesia, hypoesthesia, neuralgia, paresthesia, peripheral motor neuropathy, peripheral sensory neuropathy) (Siegel 2013)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Back pain (19% to 21%), muscle spasm (10% to 21%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased serum creatinine (17% to 25%), renal insufficiency (13%) (Siegel 2013)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (22% to 33%), dyspnea (34% to 58%), upper respiratory tract infection (19% to 21%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (30% to 58%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Cardiomyopathy (2%) (Siegel 2013), heart failure (7%) (Siegel 2013), ischemic heart disease (3%) (Siegel 2013), venous thromboembolism (2%; including deep vein thrombosis and pulmonary embolism)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypercalcemia (grades ≥3: 4%) (Siegel 2013), hyperglycemia (grades ≥3: ≤4%), hyperkalemia (grades ≥3: ≤4%), hypocalcemia (grades ≥3: ≤4%), hyponatremia (grades ≥3: 7%) (Siegel 2013), hypophosphatemia (grades ≥3: 5%) (Siegel 2013)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Febrile neutropenia (1%) (Seigel 2013)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Acute kidney injury (5%), renal failure syndrome (4%) (Siegel 2013)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Pleural effusion (4%) (Siegel 2013), pneumonia (8%), pulmonary hypertension (2%) (Siegel 2013)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Tumor lysis syndrome (Siegel 2013)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Hemoptysis (Siegel 2013), pneumonitis (Siegel 2013)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Acute myocardial infarction, hypotension, reduced ejection fraction, thromboembolic complications</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Erythema of skin, hyperhidrosis, pruritus, skin rash</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hyperuricemia, hypoalbuminemia</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain, dyspepsia, toothache, upper abdominal pain</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary tract infection</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Hemorrhage (including epistaxis, gastrointestinal hemorrhage, intracranial hemorrhage, pulmonary hemorrhage)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatic failure, increased serum transaminases (including increased serum alanine aminotransferase and increased serum aspartate aminotransferase) (Siegel 2013)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Infusion-related reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Influenza, sepsis</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Infusion-site reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Anxiety, asthenia, pain, voice disorder</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia, limb pain, musculoskeletal chest pain, musculoskeletal pain, myalgia</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision, cataract</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Tinnitus</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Acute respiratory distress syndrome, acute respiratory failure, bronchitis, bronchopneumonia, nasopharyngitis, oropharyngeal pain, pulmonary disease (acute diffuse infiltrative, including interstitial pulmonary disease), pulmonary edema, pulmonary infection, respiratory tract infection, rhinitis</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Multi-organ failure</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing (may include combination therapy):</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Pericarditis</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Acute pancreatitis, enterocolitis, gastrointestinal perforation, intestinal obstruction</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Hemolytic-uremic syndrome, thrombotic microangiopathy, thrombotic thrombocytopenic purpura</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Cytomegalovirus disease, reactivation of HBV, viremia</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Progressive multifocal leukoencephalopathy, reversible posterior leukoencephalopathy syndrome</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Chorioretinitis</p></div>
<div class="block coi drugH1Div" id="F14729173"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">There are no contraindications listed in the manufacturer's US labeling</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling: </i>Hypersensitivity to carfilzomib or any component of the formulation</p></div>
<div class="block war drugH1Div" id="F14729174"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bone marrow suppression: Thrombocytopenia (including grade 4) was observed in patients receiving carfilzomib, with platelet nadirs occurring between day 8 and day 15 of each 28-day treatment cycle and recovery to baseline by the start of the next cycle. Hemorrhage due to thrombocytopenia may occur.</p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular effects: Carfilzomib has been associated with new-onset or worsening of heart failure, pulmonary edema, decreased ejection fraction, cardiomyopathy, myocardial ischemia, and myocardial infarction (MI) (including fatalities). Some events occurred in patients with normal ventricular function at baseline. Cardiac events typically were observed throughout the course of therapy. Death caused by cardiac arrest has occurred within 1 day of carfilzomib administration. Patients ≥75 years of age have an increased risk of heart failure. Patients with NYHA class III and IV heart failure, recent MI (within 3 to 6 months), and conduction abnormalities, angina, or arrhythmias not managed by medication were excluded from clinical trials and may be at increased risk for cardiac complications; evaluate with a comprehensive medical assessment prior to initiation and closely monitor.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hemorrhage: Serious or fatal cases of hemorrhage have been reported, including GI, intracranial, and pulmonary hemorrhage and epistaxis. Bleeding may be spontaneous; intracranial hemorrhage has occurred without trauma. Hemorrhage has been reported in patients with normal or low platelet counts and has also been reported in patients who were not receiving anticoagulation or antiplatelet therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic effects: Hepatic failure, including fatal cases, has been reported rarely. Increased transaminases and hyperbilirubinemia have also been observed.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypertension: Hypertension has occurred with carfilzomib; hypertensive crisis and hypertensive emergency have also been reported (some events were fatal).</p>
<p style="text-indent:-2em;margin-left:4em;">• Infusion-related reactions: May occur immediately following or within 24 hours of carfilzomib infusion; may be life-threatening. Signs/symptoms have included fever, chills, arthralgia, myalgia, flushing, facial or laryngeal edema, vomiting, weakness, dyspnea, hypotension, syncope, chest tightness, or angina. To lessen the incidence and intensity of infusion-related reactions, administer dexamethasone prior to drug administration.</p>
<p style="text-indent:-2em;margin-left:4em;">• Posterior reversible encephalopathy syndrome: Posterior reversible encephalopathy syndrome (PRES) has been reported rarely with use; symptoms include seizure, headache, lethargy, confusion, blindness, altered consciousness, hypertension, and other visual/neurological disturbances.</p>
<p style="text-indent:-2em;margin-left:4em;">• Progressive multifocal leukoencephalopathy: Progressive multifocal leukoencephalopathy (PML), which may be fatal, has been reported; prior or concurrent immunosuppressive therapy may be a contributory factor. Consider PML with new-onset or changes in preexisting neurological signs or symptoms.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pulmonary toxicities: Acute respiratory distress syndrome (ARDS), acute respiratory failure, and acute diffuse-infiltrative pulmonary disease (eg, pneumonitis and interstitial lung disease) have occurred in a small percentage of patients (some events were fatal). In clinical trials, pulmonary arterial hypertension (PAH) was observed (including grade 3 or higher events); perform cardiac imaging or other testing as appropriate and withhold carfilzomib until PAH is resolved or returns to baseline. Dyspnea (including grade 3 or higher events) has been reported.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal toxicity: Renal toxicity (eg, renal insufficiency, acute kidney failure, kidney failure) has been reported with carfilzomib; some events have been fatal. Acute kidney failure was observed more frequently in patients receiving carfilzomib monotherapy for advanced relapsed/refractory multiple myeloma; kidney failure risk is greater when patients have a baseline reduced CrCl.</p>
<p style="text-indent:-2em;margin-left:4em;">• Thrombotic microangiopathy: Thrombotic microangiopathy, including cases of thrombocytopenic thrombotic purpura/hemolytic uremic syndrome, has been reported (some fatal).</p>
<p style="text-indent:-2em;margin-left:4em;">• Thromboembolic events: Venous thromboembolism (eg, deep vein thrombosis and pulmonary embolism) has been observed, particularly when used as part of combination therapy with dexamethasone or with lenalidomide plus dexamethasone. Thromboprophylaxis is recommended with combination therapy, and should be based on patients’ underlying risk factors, treatment regimen, and clinical status.</p>
<p style="text-indent:-2em;margin-left:4em;">• Tumor lysis syndrome: Tumor lysis syndrome (TLS), including fatalities, has been observed. TLS risk is increased in multiple myeloma patients with a high tumor burden. Adequately hydrate patients (with oral and IV fluids) prior to cycle 1 of carfilzomib therapy (and subsequent cycles if needed) and monitor closely for signs and symptoms of TLS; consider use of antihyperuricemic agents.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: The incidence of serious adverse events is higher in patients with baseline hepatic impairment (compared to patients with normal hepatic function).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Concurrent drug therapy issues:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Combination therapy toxicity: An increased incidence of serious and fatal adverse events was observed in a clinical trial comparing the combination of carfilzomib, melphalan, and prednisone (KMP) to bortezomib, melphalan, and prednisone (VMP) for the treatment of newly diagnosed multiple myeloma (MM) in transplant-ineligible patients. Cardiac failure, hypertension, acute kidney failure, and dyspnea were observed more frequently in the KMP arm. KMP is not an approved carfilzomib combination regimen.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: The incidence of serious adverse events is higher in patients ≥65 years of age (compared to patients &lt;65 years of age).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Injection: Vials contain the excipient cyclodextrin (sulfobutyl ether beta-cyclodextrin), which may accumulate in patients with renal insufficiency, although the clinical significance of this finding is uncertain (Luke 2010).</p></div>
<div class="block foc drugH1Div" id="F14729234"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Kyprolis: 10 mg (1 ea); 30 mg (1 ea); 60 mg (1 ea)</p></div>
<div class="block geq drugH1Div" id="F14729167"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F16570445"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Kyprolis Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $625.63</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">30 mg (per each): $1,876.90</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">60 mg (per each): $3,753.79</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52871463"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Kyprolis: 10 mg (1 ea); 30 mg (1 ea); 60 mg (1 ea)</p></div>
<div class="block adm drugH1Div" id="F14729226"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> Administer over 10 or 30 minutes depending on the carfilzomib dose regimen (see Dosing). Do not administer as an IV push or bolus. Hydrate with oral fluids (30 mL/kg) at least 48 hours prior to initiating cycle 1, as well as with 250 to 500 mL NS (or other appropriate IV fluid) prior to (recommended) and after (if needed) each dose in cycle 1; continue oral and/or IV hydration in subsequent cycles (if necessary). Flush line immediately before and after carfilzomib with NS or D<sub>5</sub>W. Do not administer with other medications.</p>
<p style="text-indent:-2em;margin-left:2em;">When administering as monotherapy, premedicate with dexamethasone 4 mg orally or IV when infusing carfilzomib over 10 minutes or with dexamethasone 8 mg orally or IV when infusing carfilzomib over 30 minutes. When using combination therapy, administer the recommended dexamethasone dose (refer to prescribing information). Premedicate 30 minutes to 4 hours prior to all carfilzomib doses in cycle 1, and as needed with future cycles to reduce the incidence and severity of infusion reaction.</p></div>
<div class="block hazard drugH1Div" id="F49130924"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 1]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p></div>
<div class="block use drugH1Div" id="F14641319"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Multiple myeloma, relapsed/refractory:</b></p>
<p style="text-indent:-2em;margin-left:2em;">Treatment (monotherapy) of relapsed or refractory multiple myeloma in adults who have received 1 or more lines of therapy.</p>
<p style="text-indent:-2em;margin-left:2em;">Treatment of relapsed or refractory multiple myeloma (in combination with dexamethasone, or with lenalidomide plus dexamethasone, or with daratumumab plus dexamethasone, or with daratumumab/hyaluronidase plus dexamethasone, or with isatuximab plus dexamethasone) in adults who have received 1 to 3 prior lines of therapy.</p></div>
<div class="block off-label drugH1Div" id="F46901207"><span class="drugH1">Use: Off-Label: Adult</span><p>Heart transplantation, desensitization; Kidney transplantation, desensitization; Lung transplantation, antibody-mediated rejection, treatment; Multiple myeloma, newly diagnosed; Waldenström macroglobulinemia</p></div>
<div class="block mst drugH1Div" id="F14729165"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Carfilzomib may be confused with bortezomib, ixazomib</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F14878017"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of P-glycoprotein/ABCB1 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F14878015"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">5-Aminosalicylic Acid Derivatives: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Abrocitinib: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Androgens: Hypertension-Associated Agents may enhance the hypertensive effect of Androgens. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antithymocyte Globulin (Equine): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Antithymocyte Globulin (Equine). Specifically, these effects may be unmasked if the dose of immunosuppressive therapy is reduced. Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Antithymocyte Globulin (Equine). Specifically, infections may occur with greater severity and/or atypical presentations. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Baricitinib: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Baricitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Products: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of BCG Products. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of BCG Products. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brincidofovir: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Brincidofovir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brivudine: May enhance the adverse/toxic effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chikungunya Vaccine (Live): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Chikungunya Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Chikungunya Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Systemic): Myelosuppressive Agents may enhance the myelosuppressive effect of Chloramphenicol (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Cladribine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Coccidioides immitis Skin Test: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the diagnostic effect of Coccidioides immitis Skin Test.  Management: Consider discontinuing these oncologic agents several weeks prior to coccidioides immitis skin antigen testing to increase the likelihood of accurate diagnostic results.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Adenovirus Vector): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Adenovirus Vector).  Management: Administer a 2nd dose using an mRNA COVID-19 vaccine (at least 4 weeks after the primary vaccine dose) and a bivalent booster dose (at least 2 months after the additional mRNA dose or any other boosters).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Inactivated Virus): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Inactivated Virus). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (mRNA): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of COVID-19 Vaccine (mRNA).  Management: Give a 3-dose primary series for all patients aged 6 months and older taking immunosuppressive medications or therapies. Booster doses are recommended for certain age groups. See CDC guidance for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Subunit): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Subunit). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Virus-like Particles): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Virus-like Particles). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone.  Management: Avoid the concomitant use of deferiprone and myelosuppressive agents whenever possible. If this combination cannot be avoided, monitor the absolute neutrophil count more closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dengue Tetravalent Vaccine (Live): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Dengue Tetravalent Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Dengue Tetravalent Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Denosumab: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents). Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and immunosuppressants. If combined, monitor patients for signs/symptoms of serious infections.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deucravacitinib: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: Myelosuppressive Agents may enhance the myelosuppressive effect of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Filgotinib: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hormonal Contraceptives: May enhance the thrombogenic effect of Carfilzomib. Management: Consider alternative, non-hormonal methods of contraception in patients requiring therapy with carfilzomib, especially patients using carfilzomib in combination with dexamethasone, lenalidomide plus dexamethasone, or daratumumab plus dexamethasone.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inebilizumab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Inebilizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Influenza Virus Vaccines: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Influenza Virus Vaccines.  Management: Administer influenza vaccines at least 2 weeks prior to initiating immunosuppressants if possible. If vaccination occurs less than 2 weeks prior to or during therapy, revaccinate at least 3 months after therapy discontinued if immune competence restored.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leflunomide: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Leflunomide.  Management: Increase the frequency of chronic monitoring of platelet, white blood cell count, and hemoglobin or hematocrit to monthly, instead of every 6 to 8 weeks, if leflunomide is coadministered with immunosuppressive agents.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mumps- Rubella- or Varicella-Containing Live Vaccines: May enhance the adverse/toxic effect of Immunosuppressants (Miscellaneous Oncologic Agents). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nadofaragene Firadenovec: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Natalizumab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Natalizumab. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ocrelizumab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ocrelizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ofatumumab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ofatumumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olaparib: Myelosuppressive Agents may enhance the myelosuppressive effect of Olaparib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pidotimod: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimecrolimus: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pneumococcal Vaccines: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Pneumococcal Vaccines. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Poliovirus Vaccine (Live/Trivalent/Oral): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Poliovirus Vaccine (Live/Trivalent/Oral). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Poliovirus Vaccine (Live/Trivalent/Oral). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polymethylmethacrylate: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the potential for allergic or hypersensitivity reactions to Polymethylmethacrylate.  Management: Use caution when considering use of bovine collagen-containing implants such as the polymethylmethacrylate-based Bellafill brand implant in patients who are receiving immunosuppressants. Consider use of additional skin tests prior to administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rabies Vaccine: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Rabies Vaccine.  Management: Complete rabies vaccination at least 2 weeks before initiation of immunosuppressant therapy if possible. If combined, check for rabies antibody titers, and if vaccination is for post exposure prophylaxis, administer a 5th dose of the vaccine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritlecitinib: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ritlecitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: Myelosuppressive Agents may enhance the myelosuppressive effect of Ropeginterferon Alfa-2b.  Management: Avoid coadministration of ropeginterferon alfa-2b and other myelosuppressive agents. If this combination cannot be avoided, monitor patients for excessive myelosuppressive effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ruxolitinib (Topical): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ruxolitinib (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sipuleucel-T: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Sipuleucel-T.  Management: Consider reducing the dose or discontinuing the use of immunosuppressants prior to initiating sipuleucel-T therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Solriamfetol: May enhance the hypertensive effect of Hypertension-Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sphingosine 1-Phosphate (S1P) Receptor Modulator: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Topical): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Tacrolimus (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talimogene Laherparepvec: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Talimogene Laherparepvec. Specifically, the risk of infection from the live, attenuated herpes simplex virus contained in talimogene laherparepvec may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tertomotide: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Tertomotide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Tofacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Typhoid Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Typhoid Vaccine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ublituximab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ublituximab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Upadacitinib: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Upadacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Inactivated/Non-Replicating): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating).  Management: Give inactivated vaccines at least 2 weeks prior to initiation of immunosuppressants when possible. Patients vaccinated less than 14 days before initiating or during therapy should be revaccinated at least 3 after therapy is complete.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Live): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Vaccines (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Yellow Fever Vaccine: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Yellow Fever Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Yellow Fever Vaccine. <i> Risk X: Avoid combination</i></p></div>
<div class="block rep_considerations drugH1Div" id="F52013506"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Conduct pregnancy testing prior to treatment initiation in patients who could become pregnant. Patients who could become pregnant should avoid pregnancy during carfilzomib treatment and use effective contraception during treatment and for 6 months after the last carfilzomib dose. Due to risk of thrombosis with hormonal contraception, consider an alternative method of effective contraception during combination treatment of carfilzomib with dexamethasone, lenalidomide plus dexamethasone, or daratumumab plus dexamethasone.</p>
<p style="text-indent:0em;margin-top:2em;">Patients with partners who could become pregnant should use effective contraception during treatment and for 3 months after the last carfilzomib dose.</p>
<p style="text-indent:0em;margin-top:2em;">Carfilzomib may impair fertility in males and females (based on the mechanism of action).</p></div>
<div class="block pri drugH1Div" id="F14729170"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Based on the mechanism of action and findings from animal reproduction studies, carfilzomib may cause fetal harm if administered to a pregnant patient.</p></div>
<div class="block brc drugH1Div" id="F14729172"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if carfilzomib is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Due to the potential for serious adverse reactions in the breastfed infant, breastfeeding is not recommended by the manufacturer during carfilzomib treatment and for 2 weeks after the last dose of carfilzomib.</p></div>
<div class="block mop drugH1Div" id="F14729229"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">CBC with differential and platelets (monitor frequently throughout therapy), serum potassium levels regularly during treatment, kidney function, pulmonary function (with new or worsening pulmonary symptoms), LFTs (regularly), BP (regularly throughout treatment in all patients). Pregnancy test (prior to treatment initiation) in patients who may become pregnant. Monitor for signs/symptoms of infusion-related reactions, congestive heart failure, hemorrhage (promptly evaluate symptoms of blood loss), tumor lysis syndrome, peripheral neuropathy, posterior reversible encephalopathy syndrome, progressive multifocal leukoencephalopathy, thrombocytopenic thrombotic purpura/hemolytic uremic syndrome, and venous thromboembolic events. Monitor closely for cardiac complications and evidence of volume overload due to pre- and post-hydration, particularly in patients at risk for heart failure.</p>
<p style="text-indent:-2em;margin-left:2em;">The American Society of Clinical Oncology hepatitis B virus (HBV) screening and management provisional clinical opinion (ASCO [Hwang 2020]) recommends HBV screening with hepatitis B surface antigen, hepatitis B core antibody, total Ig or IgG, and antibody to hepatitis B surface antigen prior to beginning (or at the beginning of) systemic anticancer therapy; do not delay treatment for screening/results. Detection of chronic or past HBV infection requires a risk assessment to determine antiviral prophylaxis requirements, monitoring, and follow up.</p>
<p style="text-indent:-2em;margin-left:2em;">Cardiovascular monitoring: Comprehensive assessment prior to treatment including a history and physical examination, screening for cardiovascular disease risk factors such as hypertension, diabetes, dyslipidemia, obesity, and smoking (ASCO [Armenian 2017], (ESC [Lyon 2022]). Assess BP at baseline and each clinical visit (also consider weekly home monitoring for initial 3 months, then monthly thereafter); assess natriuretic peptide at baseline for high and very high-risk patients and consider at each cycle for the first 6 cycles; consider checking natriuretic peptide at baseline for low- and moderate-risk patients; obtain a baseline echocardiography in all patients; repeat echocardiography every 3 cycles in high- and very-high risk patients and consider echocardiography every 3 cycles in low- and moderate-risk patients (ESC [Lyon 2022]).</p></div>
<div class="block pha drugH1Div" id="F14729203"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Carfilzomib inhibits proteasomes, which are responsible for intracellular protein homeostasis. Specifically, it is a potent, selective, and irreversible inhibitor of chymotrypsin-like activity of the 20S proteasome, leading to cell cycle arrest and apoptosis.</p></div>
<div class="block phk drugH1Div" id="F14729205"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>dss</sub>: 28 L (based on a 20 mg/m<sup>2</sup> dose); penetrates all tissues extensively except the brain (Kortuem 2013).</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 97%; to human plasma proteins.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Rapidly metabolized; primarily via peptidase cleavage and epoxide hydrolysis; minimal metabolism through cytochrome P450-mediated mechanisms.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Doses ≥15 mg/m<sup>2</sup>: ≤1 hour on day 1 of cycle 1.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (~25% as metabolites; &lt;1% as parent drug); feces (&lt;1% as parent drug).</p>
<p style="text-indent:-2em;margin-left:4em;">Clearance: 151 to 263 L/hour.</p></div>
<div class="block phksp drugH1Div" id="F51192702"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Patients with end-stage kidney disease requiring hemodialysis had a 33% higher AUC compared to patients with normal kidney function.</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: Patients with mild (total bilirubin 1 to 1.5 times ULN and any AST <b>or</b> total bilirubin ≤ULN and AST &gt;ULN) or moderate (bilirubin &gt;1.5 to 3 times ULN and any AST) hepatic impairment had an approximately 50% higher AUC compared to patients with normal hepatic function.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F25576764"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Kyprolis</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Alcaf | Calefir | Carfizol | Filzocar | Kyprolis</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Kyprolis</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Kyprolis</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Kyprolis</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Kyprolis</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Kyprolis</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Kyprolis</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Kyprolis | Xafilred</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Kyprolis</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Kyprolis</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Alcaf | Filzocar</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Kyprolis</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Kyprolis</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Kyprolis</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Kyprolis</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Kyprolis</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Kyprolis</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Kyprolis</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Kyprolis</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Kyprolis</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Kyprolis</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Carfilnat | Carzomib</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Kyprolis</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Kyprolis</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Kyprolis</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Kyprolis</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Kyprolis</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Kyprolis</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Kyprolis</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Kyprolis</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Kyprolis</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Kyprolis</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Kyprolis</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Kyprolis</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Kyprolis</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Kyprolis</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Kyprolis</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Kyprolis</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Kyprolis</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Kyprolis</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Kyprolis</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Kyprolis</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Kyprolis</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Kyprolis</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Kyprolis</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Kyprolis</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Kyprolis</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Kyprolis</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Kyprolis</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Kyprolis</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  &lt;800&gt; Hazardous Drugs–Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32299820">
<a name="32299820"></a>Ailawadhi S, Sexton R, Lentzsch S, et al. Low-dose versus high-dose carfilzomib with dexamethasone (S1304) in patients with relapsed-refractory multiple myeloma. <i>Clin Cancer Res</i>. 2020;26(15):3969-3978. doi:10.1158/1078-0432.CCR-19-1997<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carfilzomib-drug-information/abstract-text/32299820/pubmed" id="32299820" target="_blank">32299820</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32506824">
<a name="32506824"></a>Alishetti S, Farr M, Jennings D, et al. Desensitizing highly sensitized heart transplant candidates with the combination of belatacept and proteasome inhibition. <i>Am J Transplant</i>. 2020;20(12):3620-3630. doi:10.1111/ajt.16113<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carfilzomib-drug-information/abstract-text/32506824/pubmed" id="32506824" target="_blank">32506824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27918725">
<a name="27918725"></a>Armenian SH, Lacchetti C, Barac A, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. <i>J Clin Oncol</i>. 2017;35(8):893-911.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carfilzomib-drug-information/abstract-text/27918725/pubmed" id="27918725" target="_blank">27918725</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23364621">
<a name="23364621"></a>Badros AZ, Vij R, Martin T, et al. Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety. <i>Leukemia. </i>2013;27(8):1707-1714.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carfilzomib-drug-information/abstract-text/23364621/pubmed" id="23364621" target="_blank">23364621</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29479061">
<a name="29479061"></a>Bringhen S, Mina R, Cafro AM, et al. Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed/refractory myeloma: a phase I/II study. <i>Leukemia.</i> 2018;32(8):1803-1807. doi:10.1038/s41375-018-0024-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carfilzomib-drug-information/abstract-text/29479061/pubmed" id="29479061" target="_blank">29479061</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24855212">
<a name="24855212"></a>Bringhen S, Petrucci MT, Larocca A, et al. Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study. <i>Blood</i>. 2014;124(1):63-69. doi: 10.1182/blood-2014-03-563759.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carfilzomib-drug-information/abstract-text/24855212/pubmed" id="24855212" target="_blank">24855212</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33091356">
<a name="33091356"></a>Castillo JJ, Advani RH, Branagan AR, et al. Consensus treatment recommendations from the tenth International Workshop for Waldenström Macroglobulinaemia. <i>Lancet Haematol.</i> 2020;7(11):e827-e837. doi:10.1016/S2352-3026(20)30224-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carfilzomib-drug-information/abstract-text/33091356/pubmed" id="33091356" target="_blank">33091356</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31113777">
<a name="31113777"></a>Chari A, Martinez-Lopez J, Mateos MV, et al. Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma. <i>Blood</i>. 2019;134(5):421-431. doi:10.1182/blood.2019000722<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carfilzomib-drug-information/abstract-text/31113777/pubmed" id="31113777" target="_blank">31113777</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30776902">
<a name="30776902"></a>Colvin MM, Cook JL, Chang PP, et al; American Heart Association Heart Failure and Transplantation Committee of the Council on Clinical Cardiology; Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; and Council on Cardiovascular Surgery and Anesthesia. Sensitization in heart transplantation: Emerging knowledge: A scientific statement from the American Heart Association. <i>Circulation</i>. 2019;139(12):e553-e578. doi:10.1161/CIR.0000000000000598<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carfilzomib-drug-information/abstract-text/30776902/pubmed" id="30776902" target="_blank">30776902</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32682484">
<a name="32682484"></a>Dimopoulos M, Quach H, Mateos MV, et al. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study. <i>Lancet</i>. 2020;396(10245):186-197. doi:10.1016/S0140-6736(20)30734-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carfilzomib-drug-information/abstract-text/32682484/pubmed" id="32682484" target="_blank">32682484</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26671818">
<a name="26671818"></a>Dimopoulos MA, Moreau P, Palumbo A, et al; ENDEAVOR investigators. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomized, phase 3, open-label, multicenter study. <i>Lancet Oncol</i>. 2016a;17(1):27-38.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carfilzomib-drug-information/abstract-text/26671818/pubmed" id="26671818" target="_blank">26671818</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26976420">
<a name="26976420"></a>Dimopoulos MA, Sonneveld P, Leung N, et al. International Myeloma Working Group recommendations for the diagnosis and management of myeloma-related renal impairment. <i>J Clin Oncol.</i> 2016b;34(13):1544-1557.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carfilzomib-drug-information/abstract-text/26976420/pubmed" id="26976420" target="_blank">26976420</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28173620">
<a name="28173620"></a>Ensor CR, Yousem SA, Marrari M, et al. Proteasome inhibitor carfilzomib-based therapy for antibody-mediated rejection of the pulmonary allograft: use and short-term findings. <i>Am J Transplant</i>. 2017;17(5):1380-1388. doi:10.1111/ajt.14222<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carfilzomib-drug-information/abstract-text/28173620/pubmed" id="28173620" target="_blank">28173620</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33939491">
<a name="33939491"></a>Griggs JJ, Bohlke K, Balaban EP, et al. Appropriate systemic therapy dosing for obese adult patients with cancer: ASCO guideline update. <i>J Clin Oncol</i>. 2021;39(18):2037-2048. doi:10.1200/JCO.21.00471<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carfilzomib-drug-information/abstract-text/33939491/pubmed" id="33939491" target="_blank">33939491</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32716741">
<a name="32716741"></a>Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. <i>J Clin Oncol</i>. 2020;38(31):3698-3715. doi:10.1200/JCO.20.01757<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carfilzomib-drug-information/abstract-text/32716741/pubmed" id="32716741" target="_blank">32716741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24518527">
<a name="24518527"></a>Jhaveri KD, Chidella S, Varghese J, Mailloux L, Devoe C. Carfilzomib-related acute kidney injury. <i>Clin Adv Hematol Oncol</i>. 2013;11(9):604-605.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carfilzomib-drug-information/abstract-text/24518527/pubmed" id="24518527" target="_blank">24518527</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23393020">
<a name="23393020"></a>Kortuem KM and Stewart AK. Carfilzomib. <i>Blood.</i> 2013;121(6):893-897.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carfilzomib-drug-information/abstract-text/23393020/pubmed" id="23393020" target="_blank">23393020</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24518528">
<a name="24518528"></a>Kwon D, Niesvizky R. Treatment of multiple myeloma with carfilzomib in patients with renal injury. <i>Clin Adv Hematol Oncol.</i> 2013;11(9):605-606.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carfilzomib-drug-information/abstract-text/24518528/pubmed" id="24518528" target="_blank">24518528</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Kyprolis (carfilzomib) [prescribing information]. Thousand Oaks, CA: Onyx Pharmaceuticals Inc; June 2022.</div>
</li>
<li>
<div class="reference">
                  Kyprolis (carfilzomib) [product monograph]. Mississauga, Ontario, Canada: Amgen Canada Inc; January 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27432877">
<a name="27432877"></a>Leblond V, Kastritis E, Advani R, et al. Treatment recommendations from the Eighth International Workshop on Waldenström's Macroglobulinemia. <i>Blood</i>. 2016;128(10):1321-1328.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carfilzomib-drug-information/abstract-text/27432877/pubmed" id="27432877" target="_blank">27432877</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20213839">
<a name="20213839"></a>Luke DR, Tomaszewski K, Damle B, Schlamm HT. Review of the basic and clinical pharmacology of sulfobutylether-beta-cyclodextrin (SBECD). <i>J Pharm Sci</i>. 2010;99(8):3291-3301.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carfilzomib-drug-information/abstract-text/20213839/pubmed" id="20213839" target="_blank">20213839</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36017568">
<a name="36017568"></a>Lyon AR, López-Fernández T, Couch LS, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). <i>Eur Heart J</i>. 2022;43(41):4229-4361. doi:10.1093/eurheartj/ehac244<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carfilzomib-drug-information/abstract-text/36017568/pubmed" id="36017568" target="_blank">36017568</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33475778">
<a name="33475778"></a>Mian HS, Fiala MA, Sanchez L, Vij R, Wildes TM. Renal failure among multiple myeloma patients utilizing carfilzomib and associated factors in the "real world". <i>Ann Hematol</i>. 2021;100(5):1261-1266. doi:10.1007/s00277-021-04420-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carfilzomib-drug-information/abstract-text/33475778/pubmed" id="33475778" target="_blank">33475778</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Moreau.1">
<a name="Moreau.1"></a>Moreau P, Chari A, Haenel M, et al. Subcutaneous daratumumab (DARA SC) plus standard-of-care (SoC) regimens in multiple myeloma (MM) across lines of therapy in the phase 2 pleiades study: initial results of the DARA SC plus carfilzomib/dexamethasone (D-Kd) cohort, and updated results for the DARA SC plus bortezomib/melphalan/prednisone (D-VMP) and DARA SC plus lenalidomide/dexamethasone (D-Rd) cohorts. <i>Blood.</i> 2020;136(suppl 1):28-30. https://ashpublications.org/blood/article/136/Supplement%201/28/471077/Subcutaneous-Daratumumab-DARA-SC-Plus-Standard-of. Accessed December 8, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34097854">
<a name="34097854"></a>Moreau P, Dimopoulos MA, Mikhael J, et al; IKEMA study group. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. <i>Lancet</i>. 2021;397(10292):2361-2371. doi:10.1016/S0140-6736(21)00592-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carfilzomib-drug-information/abstract-text/34097854/pubmed" id="34097854" target="_blank">34097854</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29866475">
<a name="29866475"></a>Moreau P, Mateos MV, Berenson JR, et al. Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study [published correction appears in <i>Lancet Oncol</i>. 2018;19(8):e382]. <i>Lancet Oncol</i>. 2018;19(7):953-964. doi: 10.1016/S1470-2045(18)30354-1.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carfilzomib-drug-information/abstract-text/29866475/pubmed" id="29866475" target="_blank">29866475</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25225420">
<a name="25225420"></a>Papadopoulos KP, Siegel DS, Vesole DH, et al. Phase I study of 30-minute infusion of carfilzomib as single agent or in combination with low-dose dexamethasone in patients with relapsed and/or refractory multiple myeloma. <i>J Clin Oncol</i>. 2015;33(7):732-739. doi: 10.1200/JCO.2013.52.3522.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carfilzomib-drug-information/abstract-text/25225420/pubmed" id="25225420" target="_blank">25225420</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33748409">
<a name="33748409"></a>Pham C, Pierce BJ, Nguyen DT, Graviss EA, Huang HJ. Assessment of carfilzomib treatment response in lung transplant recipients with antibody-mediated rejection. <i>Transplant Direct</i>. 2021;7(4):e680. doi:10.1097/TXD.0000000000001131<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carfilzomib-drug-information/abstract-text/33748409/pubmed" id="33748409" target="_blank">33748409</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36506224">
<a name="36506224"></a>Philipponnet C, Aniort J, Atenza A, Heng AE, Souweine B. Carfilzomib induced microangiopathy due to accumulation with paxlovid. <i>Kidney Int Rep</i>. 2022;7(12):2746-2749. doi:10.1016/j.ekir.2022.09.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carfilzomib-drug-information/abstract-text/36506224/pubmed" id="36506224" target="_blank">36506224</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28424963">
<a name="28424963"></a>Quach H, White D, Spencer A, et al. Pharmacokinetics and safety of carfilzomib in patients with relapsed multiple myeloma and end-stage renal disease (ESRD): an open-label, single-arm, phase I study. <i>Cancer Chemother Pharmacol</i>. 2017;79(6):1067-1076.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carfilzomib-drug-information/abstract-text/28424963/pubmed" id="28424963" target="_blank">28424963</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33461512">
<a name="33461512"></a>Rassner M, Baur R, Wäsch R, et al. Two cases of carfilzomib-induced thrombotic microangiopathy successfully treated with eculizumab in multiple myeloma. <i>BMC Nephrol</i>. 2021;22(1):32. doi:10.1186/s12882-020-02226-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carfilzomib-drug-information/abstract-text/33461512/pubmed" id="33461512" target="_blank">33461512</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36049718">
<a name="36049718"></a>Razia D, Hu C, Cherrier L, Nasar A, Walia R, Tokman S. Carfilzomib versus rituximab for treatment of de novo donor-specific antibodies in lung transplant recipients. <i>Transpl Immunol</i>. 2022;75:101703. doi:10.1016/j.trim.2022.101703<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carfilzomib-drug-information/abstract-text/36049718/pubmed" id="36049718" target="_blank">36049718</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27018162">
<a name="27018162"></a>Richter J, Biran N, Duma N, Vesole DH, Siegel D. Safety and tolerability of pomalidomide-based regimens (pomalidomide-carfilzomib-dexamethasone with or without cyclophosphamide) in relapsed/refractory multiple myeloma and severe renal dysfunction: a case series. <i>Hematol Oncol.</i> 2017;35(2):246-251. doi:10.1002/hon.2290<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carfilzomib-drug-information/abstract-text/27018162/pubmed" id="27018162" target="_blank">27018162</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26384354">
<a name="26384354"></a>Shah JJ, Stadtmauer EA, Abonour R, et al. Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma. <i>Blood</i>. 2015;126(20):2284-2290. doi:10.1182/blood-2015-05-643320<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carfilzomib-drug-information/abstract-text/26384354/pubmed" id="26384354" target="_blank">26384354</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23935022">
<a name="23935022"></a>Siegel D, Martin T, Nooka A, et al. Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies. <i>Haematologica</i>. 2013;98(11):1753-1761.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carfilzomib-drug-information/abstract-text/23935022/pubmed" id="23935022" target="_blank">23935022</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22833546">
<a name="22833546"></a>Siegel DS, Martin T, Wang M, et al. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. <i>Blood</i>. 2012;120(14):2817-2825. doi:10.1182/blood-2012-05-425934<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carfilzomib-drug-information/abstract-text/22833546/pubmed" id="22833546" target="_blank">22833546</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33785250">
<a name="33785250"></a>Sriwattanakomen R, Xu Q, Demehin M, et al. Impact of carfilzomib-based desensitization on heart transplantation of sensitized candidates. <i>J Heart Lung Transplant</i>. 2021;40(7):595-603. doi:10.1016/j.healun.2021.03.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carfilzomib-drug-information/abstract-text/33785250/pubmed" id="33785250" target="_blank">33785250</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25482145">
<a name="25482145"></a>Stewart AK, Rajkumar SV, Dimopoulos MA, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. <i>N Engl J Med</i>. 2015;372(2):142-152.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carfilzomib-drug-information/abstract-text/25482145/pubmed" id="25482145" target="_blank">25482145</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31550069">
<a name="31550069"></a>Tremblay S, Driscoll JJ, Rike-Shields A, et al. A prospective, iterative, adaptive trial of carfilzomib-based desensitization. <i>Am J Transplant</i>. 2020;20(2):411-421. doi:10.1111/ajt.15613<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carfilzomib-drug-information/abstract-text/31550069/pubmed" id="31550069" target="_blank">31550069</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24859363">
<a name="24859363"></a>Treon SP, Tripsas CK, Meid K, et al. Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenström's macroglobulinemia. <i>Blood.</i> 2014;124(4):503-510.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carfilzomib-drug-information/abstract-text/24859363/pubmed" id="24859363" target="_blank">24859363</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed October 5, 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37080658">
<a name="37080658"></a>Velleca A, Shullo MA, Dhital K, et al. The International Society for Heart and Lung Transplantation (ISHLT) guidelines for the care of heart transplant recipients.<i> J Heart Lung Transplant</i>. 2023;42(5):e1-e141. doi:10.1016/j.healun.2022.10.015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carfilzomib-drug-information/abstract-text/37080658/pubmed" id="37080658" target="_blank">37080658</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22555973">
<a name="22555973"></a>Vij R, Wang M, Kaufman JL, et al. An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma. <i>Blood</i>. 2012; 119(24):5661-5670.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carfilzomib-drug-information/abstract-text/22555973/pubmed" id="22555973" target="_blank">22555973</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 86042 Version 270.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
